<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720447</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-BRD-07-137</org_study_id>
    <secondary_id>CDR0000597903</secondary_id>
    <secondary_id>EUDRACT 2007-003081-18</secondary_id>
    <nct_id>NCT00720447</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma</brief_title>
  <official_title>Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell&#xD;
      transplant helps stop the growth of cancer cells. It also helps stop the patient's immune&#xD;
      system from rejecting the donor's stem cells. When the healthy stem cells from a donor are&#xD;
      infused into the patient they may help the patient's bone marrow make stem cells, red blood&#xD;
      cells, white blood cells, and platelets.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying donor stem cell transplant in treating patients with&#xD;
      mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine progression-free survival in patients with mantle cell lymphoma undergoing&#xD;
           low-intensity allogeneic stem cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine overall survival of these patients.&#xD;
&#xD;
        -  Determine the toxicity by way of adverse event profile of this regimen in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Reduced intensity conditioning: Patients receive carmustine IV over 2 hours on day -6,&#xD;
           etoposide IV over 1 hour and cytarabine IV over 15 minutes on days -5 to -2, alemtuzumab&#xD;
           IV over 2 hours on days -5 to -1, and melphalan IV on day -1.&#xD;
&#xD;
        -  Donor stem cell transplant: Patients undergo stem cell transplantation on day 0 with&#xD;
           filgrastim (G-CSF)-mobilized peripheral blood stem cells or bone marrow stem cells.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV or orally&#xD;
           on day -1 to 30 and taper to day 100.&#xD;
&#xD;
        -  Donor lymphocyte infusion (DLI) therapy: Patients with evidence of disease progression,&#xD;
           mixed chimerism, or low level residual disease undergo DLI every 3 months for up to 15&#xD;
           months in the absence of GVHD.&#xD;
&#xD;
      After completion of study, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>donor lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of mantle cell lymphoma&#xD;
&#xD;
          -  No relapsed or progressive disease&#xD;
&#xD;
          -  Achieved at least a partial remission following induction chemotherapy&#xD;
&#xD;
          -  HLA-matched donor available&#xD;
&#xD;
          -  Blood samples from both patient and donor available for chimerism studies&#xD;
&#xD;
          -  No central nervous system involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 2-4&#xD;
&#xD;
          -  Considered fit for transplant by treating physician&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Ejection fraction &gt; 50% (no inadequate cardiac function)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No symptomatic respiratory compromise&#xD;
&#xD;
          -  No serious concurrent disease which would preclude allograft&#xD;
&#xD;
          -  No known serological positivity for hepatitis B, hepatitis C, or HIV&#xD;
&#xD;
          -  No history of a psychological illness or condition that would affect compliance&#xD;
&#xD;
          -  No previous malignancy within the past 5 years except nonmelanoma skin tumors or stage&#xD;
             0 (in situ) cervical carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Rule, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derriford Hospital</affiliation>
  </overall_official>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

